


**Newly Reported Drugs:** The following drugs were reported to NFLIS-Drug for the first time between **July 1, 2020, and September 30, 2020**, and were submitted to a NFLIS participating laboratory on or after July 1, 2019.




### Midwest

N-(1,4-Dimethylpentyl)-3,4-DMA




Chlorofentanyl



### South

Ocfentanil



### Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present the top five drug reports in each category received by NFLIS-Drug between July 1, 2020, and September 30, 2020, that were submitted to a NFLIS participating laboratory on or after July 1, 2019.

<sup>1</sup> Includes all positional and nonspecified isomers as reported by participating laboratories.

Synthetic Cannabinoids	1,927
Fluoro-MDMB-PICA <sup>1</sup>	855
MDMB-4en-PINACA	359
Fluoro-MDMB-BUTINACA <sup>1</sup>	264
5F-ADB	89
EMB-FUBINACA	24

Synthetic Cathinones	2,371
Eutylone	1,931
BMDP	92
N-Ethylpentylone	44
Butylpentylone <sup>1</sup>	44
alpha-PiHP	35

Cannabinoids	39,921
Cannabis/THC	38,454
Cannabidiol	1,012
Cannabinol	168
Tetrahydrocannabinolic acid A	129
Delta-8-tetrahydrocannabinol	68

Depressants and Tranquilizers	9,590
Alprazolam	3,727
Clonazepam	1,294
Flualprazolam	1,115
Etizolam	803
PCP	475


Phenethylamines	81,324
Methamphetamine	78,290
Amphetamine	1,690
MDMA	898
Lisdexamfetamine	178
MDA	104

Fentanyl and Fentanyl-Related Compounds	24,391
Fentanyl	20,838
ANPP	2,127
Acetyl fentanyl	916
Carfentanil	178
Valeryl fentanyl	150


### Spotlight: Xylazine

Xylazine is a prescription veterinary drug often found as an adulterant in illicit substances. Xylazine reports have increased in recent years. Through October 26, 2020, NFLIS-Drug received **816** reports of xylazine from items that were submitted to a participating laboratory in 2020. Of those items, **84%** contained at least one other identified drug. Fentanyl was present in **96%** of items containing xylazine and at least one other drug, and it accounted for **50%** of all drugs reported in combination with xylazine.


Xylazine: 2016–2020



Percentage of All 2020 Items Containing Xylazine and at Least One Other Drug



Percentage of Drugs Reported in Combination with Xylazine in 2020<sup>2</sup>



<sup>2</sup> Percentages may not sum to 100% because of rounding.

**Data Disclaimer:** Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in October 2020 and include drug reports received by NFLIS-Drug through October 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. Drugs reported in combination with xylazine are not necessarily counts of true combinations (e.g., powders mixed together), but also include counts of separate drugs reported together in the same item. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/Reports.aspx>. Questions and comments: [DEANFLIS@rti.org](mailto:DEANFLIS@rti.org).

